Patient compliance and outcomes

Inflammatory Bowel Diseases

Volumn 5, Issue 2, 1999, Pages 134-137

  Kane, Sunanda ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CROHN DISEASE; HUMAN; PATIENT COMPLIANCE; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

CLINICAL TRIALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 0033125896     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-199905000-00009     Document Type: Review

References (26)

1. The Mesalamine Study Group. An oral preparation of mesalamine as long-term naintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996;124:204-11.
2. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. [Comments]. Gastroenterology 1993: 104:435-9.
3. Horwitz RAH, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med 1993;153:1863-8.
4. Riley S, Mani V, Goddman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 1990;31:179-83.
5. Monane M, Bohn RL, Gurwitz JH, et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender and race. Am J Public Health 1996;86:1805-8.
6. McDermott M, Schmitt B, Wallner E. Impact of medication non-adherence on coronary heart disease outcomes. Arch Intern Med 1997;157:1921-9.
7. Wiebe J, Christensen AJ. Patient adherence in chronic illness: personality and coping in context. J Pers 1996;64:815-35.
8. Das K, Eastwood MA, McManus JPA, Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. Gut 1973;14:631-41.
9. Cowan GO, Das KM, Eastwood MA. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis. Br Med J 1977;2:1057-9.
10. van Hees PA, van Tongeren JH. Conpliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4:333-6.
11. Dickinson RJ, King A, Wight DG, Hunter JO, Neale G. Is continuous sulfasalazine necessary in the management of patients with ulcerative colitis? Results of a preliminary study. Dis Colon Rectum 1985;28:929-30.
12. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117-20.
13. Moody GA, Jayanthi V, Probent CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-83.
14. Odes HS. 5-Aminosalicylic acid 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis. J Clin Gastroenterol 1997;24:287-8.
15. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
16. Cuffari C, Seidman EG, Latour S, et al. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 1996;74:580-5.
17. Levenstein S, Prantera S, Luzi C, et al. Low residue or normal diet in Crohn's disease: a prospective controlled study in Italian patients. Gut 1985;26:989-93.
18. Imes S, Pinchbeck B, Dinwoodie A, et al. Effect of Ensure, a defined formula diet, in patients with Crohn's disease. Digestion 1986;35:158-69.
19. Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study group members (German Crohn's disease study group). Scand J Gastroenterol 1996;31:778-85.
20. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia [Comments]. Gastroenterology 1992;103:431-8.
21. Calkins D, Davis RB, Reiley P, et al. Patient-physician communication at hospital discharge and patients' understanding of the postdischarge treatment plan. Arch Intern Med 1997;157:1026-30.
22. Robinson RJ, Hart AR, Mayberry JF. Cancer surveillance in ulcerative colitis: a survey of patients' knowledge. Endoscopy 1996; 28:761-2.
23. Martin A, Leone L, Castagliuolo J, et al. What do patients want to know about their inflammatory bowel disease? Ital J Gastroenterol 1992;24:477-80.
24. Drossman DA, Leserman J, Li ZM, et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991;53:701-12.
25. Von Korff M, Gruman J, Schaefer J, Curry SJ, Wagner EH. Collaborative management of chronic illness. Ann Intern Med 1997; 127:1097-1102.
26. Farup PG, Houde O, Halvorsen FA, et al. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol 1995;30:164-70.